Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease
Recruitment status was: Active, not recruiting
RATIONALE: Fludarabine may be an effective treatment for graft-versus-host disease caused by bone marrow transplantation.
PURPOSE: Phase I/II trial to study the effectiveness of fludarabine in treating patients who have chronic graft-versus-host disease that has not responded to steroid therapy.
|Study Design:||Primary Purpose: Supportive Care|
|Official Title:||A Phase I-II Study for the Treatment of Steroid Resistant GVHD With Fludarabine|
OBJECTIVES: I. Determine the maximum tolerated dose, toxicity, and efficacy of fludarabine in patients with steroid resistant chronic graft versus host disease.
OUTLINE: This is a dose escalation study. Phase I: Patients receive fludarabine IV over less than 30 minutes for 1-3 days. Treatment repeats every 4 weeks for up to 4 courses in the absence of relapse of underlying disease, malignancy, graft rejection, or unacceptable toxicity. Patients with progressive graft versus host disease after completion of 3 courses are taken off study. Patients with complete response are taken off study. Patients with partial response may continue treatment at the immediate prior dose level. Cohorts 3-6 patients receive escalating doses of fludarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose limiting toxicity. Phase II: Patients receive fludarabine at the MTD from phase I of the study.
PROJECTED ACCRUAL: A total of 15-27 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004194
|Study Chair:||Christos E. Emmanouilides, MD||Jonsson Comprehensive Cancer Center|